SCHEMBL472044

SCHEMBL472044

N=[P](N)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31376856 0.72
SCHEMBL3216693 0.72
SCHEMBL8626057 0.72
SCHEMBL3667891 0.72
SCHEMBL16741 0.72
Guanidine SCHEMBL15924672 0.67
Hydroxyamine SCHEMBL272868 0.67
Hydrochloric Acid SCHEMBL3442206 0.67
Phosphine SCHEMBL20595760 0.67
SCHEMBL7901642 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547631-B2 Organometallic compounds ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2009-06-16 US claimed
EP-1887012-A2 Organometallic compounds for chemical vapour deposition and atomic layer deposition of thin films Rohm and Haas Electronic Materials LLC (US) 2008-02-13 EP claimed
US-20080026577-A1 Organometallic compounds ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2008-01-31 US claimed
US-20230241217-A1 HYDROGEL IRRADIATION ASCENDIS PHARMA A/S (DK) 2023-08-03 US disclosed
WO-2023110727-A2 NOVEL CANCER TREATMENTS WITH TLR7/8 AGONISTS Ascendis Pharma Oncology Division A/S (DK) 2023-06-22 WO disclosed
US-20230102309-A1 TYROSINE KINASE INHIBITOR CONJUGATES Ascendis Pharma Oncology Division A/S (DE) 2023-03-30 US disclosed
EP-4146281-A1 HYDROGEL IRRADIATION Ascendis Pharma A/S (DK) 2023-03-15 EP disclosed
US-20230055021-A1 METHODS FOR TREATING PSYCHIATRIC DISORDERS OR SYMPTOMS THEREOF USING NCAM PEPTIDE MIMETICS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-02-23 US disclosed
US-20220396629-A1 RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF GENMAB A/S (DK) 2022-12-15 US disclosed
EP-3986479-A1 ANTI-CTLA4 CONJUGATES Ascendis Pharma Oncology Division A/S (DK) 2022-04-27 EP disclosed
EP-3986478-A1 TYROSINE KINASE INHIBITOR CONJUGATES Ascendis Pharma Oncology Division A/S (DK) 2022-04-27 EP disclosed
WO-2005030804-A2 A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION AND/OR SYNAPTIC PLASTICITY ENKAM PHARMACEUTICALS A/S (DK) 2005-04-07 WO disclosed
WO-2005028512-A1 PRO-INFLAMMATORY AND ANTI-INFLAMMATORY ANTIBODIES AGAINST THE HEPARIN-BINDING PROTEIN (HBP) LEUKOTECH A/S (DK) 2005-03-31 WO disclosed
EP-1515997-A1 YTTRIUM-BASED ETHYLENE POLYMERIZATION CATALYSTS WITH BULKY AMIDINATE ANCILLARY LIGANDS ExxonMobil Chemical Patents Inc. (US) 2005-03-23 EP disclosed
WO-2005014623-A2 COMPOUNDS COMPRISING LPA ENKAM PHARMACEUTICALS A/S (DK) 2005-02-17 WO disclosed
WO-2004024925-A2 COLLECTIN-COMPLEMENT ACTIVATING PROTEIN CHIMERAS NATIMMUNE A/S (DK) 2004-03-25 WO disclosed
WO-2004016653-A2 BACTERICIDAL, ANTI-APOPTOTIC, PRO-INFLAMMATORY AND ANTI-INFLAMMATORY PEPTIDES OF HEPARIN-BINDING PROTEIN (HBP) OR HUMAN NEUTROPHIL ELASTASE LEUKOTECH A/S (DK) 2004-02-26 WO disclosed
US-20040033889-A1 Yttrium-based ethylene polymerization catalysts with bulky amidinate ancillary ligands EXXONMOBIL CHEMICAL PATENTS INC. 2004-02-19 US disclosed
WO-2004000894-A1 YTTRIUM-BASED ETHYLENE POLYMERIZATION CATALYSTS WITH BULKY AMIDINATE ANCILLARY LIGANDS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2003-12-31 WO disclosed
WO-2003080660-A2 METHOD FOR THE PREPARATION OF RECOMBINANT MAMMALIAN HEPARIN-BINDING PROTEIN (HBP) LEUKOTECH A/S (DK) 2003-10-02 WO disclosed